hameln pharma ApS: Financial statements 2021
CVR: 39720213
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
hameln pharma ApS (CVR 39720213) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 1,874,153 and a net result of DKK 1,416,578 compared with DKK 1,863,764 the year before. That is a decrease of 22% compared with the year before. Equity in the 2021 report amounted to DKK 3,247,611. The solvency ratio was 62.4%.
- Gross Profit
- DKK 1,874,153
- Profit/Loss
- DKK 1,416,578
- Equity
- DKK 3,247,611
- Total Assets
- DKK 5,207,493
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 1.9 mio. | 1.4 mio. | 3.2 mio. | 0 |
| 2020 | - | 2.4 mio. | 1.9 mio. | 1.8 mio. | 0 |
Official annual report
Find more companies like hameln pharma ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
Hameln pharma ApS has published its annual report for 2020. Gross profit came to DKK 2,403,938, and the net result was DKK 1,863,764.
As of July 5, 2021, Marina Alexandra Stock is registered as director of hameln pharma ApS.
As of July 5, 2021, Frank Jahrand is registered as director of hameln pharma ApS.
As of July 5, 2021, Dr. Christopher Klein has stepped down as director of hameln pharma ApS.
About hameln pharma ApS
hameln pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Frank Jahrand and Stephen Allen Watkin. The company is owned by hameln pharma gmbh. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 10,300,176 and a net result of DKK 8,050,599 compared with DKK 5,288,671 the year before. Equity in the 2025 report amounted to DKK 20,334,774.